Addition Of Bevacizumab To Conventional Therapy Improved Progression-Free Survival In

[News]

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D...

More... (http://www.medicalnewstoday.com/releases/238841.php)